<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04298840</url>
  </required_header>
  <id_info>
    <org_study_id>2019-997</org_study_id>
    <nct_id>NCT04298840</nct_id>
  </id_info>
  <brief_title>Influence of Creatine Monohydrate Supplementation on Androgens and Global Hair Assessments</brief_title>
  <official_title>Influence of Creatine Monohydrate Supplementation on Androgens and Global Hair Assessments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Tech University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Legion Athletics, Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Texas Tech University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled trial examining the effects of&#xD;
      creatine monohydrate supplementation on androgens and hair loss in free-living adult males.&#xD;
      Participants will complete 6 months of supplementation of 5 grams per day of creatine&#xD;
      monohydrate while following their normal lifestyle practices. At baseline and six months&#xD;
      after study initiation, participants will complete laboratory assessments. These assessments&#xD;
      will include a standard blood draw for evaluation of total testosterone (T), free T,&#xD;
      dihydrotestosterone (DHT), and DHT:T ratios in the blood, as well as global photography and&#xD;
      questionnaires to evaluate hair loss. This study will examine the claim that creatine&#xD;
      increases DHT concentrations and and DHT:T ratio, as well as provide novel data regarding&#xD;
      whether creatine promotes hair loss.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor indicated it was unable/unwilling to support project at the present time.&#xD;
  </why_stopped>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized to receive creatine monohydrate or placebo for daily consumption during the study period.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dihydrotestosterone</measure>
    <time_frame>6 months</time_frame>
    <description>Blood concentration of dihydrotestosterone.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dihydrotestosterone-to-Testosterone Ratio 1</measure>
    <time_frame>6 months</time_frame>
    <description>Ratio of dihydrotestosterone to total testosterone in the blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dihydrotestosterone-to-Testosterone Ratio 2</measure>
    <time_frame>6 months</time_frame>
    <description>Ratio of dihydrotestosterone to free testosterone in the blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Testosterone</measure>
    <time_frame>6 months</time_frame>
    <description>Total testosterone in the blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Free Testosterone</measure>
    <time_frame>6 months</time_frame>
    <description>Free testosterone in the blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Global Hair Assessments</measure>
    <time_frame>6 months</time_frame>
    <description>Subjectively scored assessment of changes in hair properties from baseline to the end of the intervention. Assessor will be a blinded expert.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self-Reported Hair Assessments</measure>
    <time_frame>6 months</time_frame>
    <description>Survey allowing for participant-reported changes in hair properties as a result of the intervention.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Dihydrotestosterone</condition>
  <condition>Testosterone</condition>
  <condition>Hair Loss</condition>
  <arm_group>
    <arm_group_label>Creatine Monohydrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Creatine Monohydrate Supplementation</intervention_name>
    <description>Participants in the creatine monohydrate supplementation arm will consume 5 grams per day of creatine monohydrate.</description>
    <arm_group_label>Creatine Monohydrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo Supplementation</intervention_name>
    <description>Participants in the placebo supplementation arm will consume 5 grams per day of maltodextrin placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male between the ages of 18 and 35&#xD;
&#xD;
          -  Weight of at least 110 pounds&#xD;
&#xD;
          -  Generally healthy (defined as an absence of a disease or medical condition which could&#xD;
             potentially be negatively influenced by study participation or confound study results)&#xD;
&#xD;
          -  Low levels of habitual creatine consumption, defined as consuming an average of &lt;10&#xD;
             g/week of creatine from all supplemental sources within the three months prior to&#xD;
             study initiation&#xD;
&#xD;
          -  Willingness to report to baseline and final assessments with a similar haircut (i.e.&#xD;
             willingness to replicate baseline haircut prior final assessment, to the best of his&#xD;
             ability) and one that allows for evaluation of hair growth patterns (e.g., not a&#xD;
             completely shaved head that disallows visualization of the hairline)&#xD;
&#xD;
          -  Willingness to adhere to the supplementation protocol for the duration of the study&#xD;
             (i.e., 6 months of daily supplementation with 5 grams per day of creatine monohydrate&#xD;
             or placebo) and abstain from additional creatine supplement ingestion during this&#xD;
             time.&#xD;
&#xD;
          -  Willingness to abstain from any treatments related to hair loss or hair growth for the&#xD;
             duration of the study&#xD;
&#xD;
          -  Willingness to maintain normal practices regarding hair products (i.e. continue to use&#xD;
             regular shampoo, conditioner, and other products over the duration of the study and&#xD;
             abstain from switching products during the study if at all possible)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Failing to meet any of the aforementioned inclusion criteria&#xD;
&#xD;
          -  Presence of pacemaker or any electrical device (due to electrical currents&#xD;
             administered by bioimpedance devices used to assess body composition)&#xD;
&#xD;
          -  Individual currently participates in any type of hair loss treatment or procedure or&#xD;
             has undergone any such treatment or procedure within the last 12 months&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grant M Tinsley, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Tech University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Kinesiology &amp; Sport Management</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>van der Merwe J, Brooks NE, Myburgh KH. Three weeks of creatine monohydrate supplementation affects dihydrotestosterone to testosterone ratio in college-aged rugby players. Clin J Sport Med. 2009 Sep;19(5):399-404. doi: 10.1097/JSM.0b013e3181b8b52f.</citation>
    <PMID>19741313</PMID>
  </reference>
  <reference>
    <citation>Kreider RB, Kalman DS, Antonio J, Ziegenfuss TN, Wildman R, Collins R, Candow DG, Kleiner SM, Almada AL, Lopez HL. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. J Int Soc Sports Nutr. 2017 Jun 13;14:18. doi: 10.1186/s12970-017-0173-z. eCollection 2017. Review.</citation>
    <PMID>28615996</PMID>
  </reference>
  <reference>
    <citation>Kaufman KD. Androgens and alopecia. Mol Cell Endocrinol. 2002 Dec 30;198(1-2):89-95. Review.</citation>
    <PMID>12573818</PMID>
  </reference>
  <reference>
    <citation>Tr√ºeb RM. Molecular mechanisms of androgenetic alopecia. Exp Gerontol. 2002 Aug-Sep;37(8-9):981-90. Review.</citation>
    <PMID>12213548</PMID>
  </reference>
  <reference>
    <citation>Bang HJ, Yang YJ, Lho DS, Lee WY, Sim WY, Chung BC. Comparative studies on level of androgens in hair and plasma with premature male-pattern baldness. J Dermatol Sci. 2004 Feb;34(1):11-6.</citation>
    <PMID>14757277</PMID>
  </reference>
  <reference>
    <citation>Olsen EA, Whiting DA, Savin R, Rodgers A, Johnson-Levonas AO, Round E, Rotonda J, Kaufman KD; Male Pattern Hair Loss Study Group. Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo. J Am Acad Dermatol. 2012 Sep;67(3):379-86. doi: 10.1016/j.jaad.2011.10.027. Epub 2012 Feb 9.</citation>
    <PMID>22325459</PMID>
  </reference>
  <reference>
    <citation>Van Neste MD. Assessment of hair loss: clinical relevance of hair growth evaluation methods. Clin Exp Dermatol. 2002 Jul;27(5):358-65. Review.</citation>
    <PMID>12190635</PMID>
  </reference>
  <reference>
    <citation>Ashique K, Kaliyadan F. Clinical photography for trichology practice: tips and tricks. Int J Trichology. 2011 Jan;3(1):7-13. doi: 10.4103/0974-7753.82118.</citation>
    <PMID>21769229</PMID>
  </reference>
  <reference>
    <citation>Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975 Nov;68(11):1359-65.</citation>
    <PMID>1188424</PMID>
  </reference>
  <reference>
    <citation>Gupta M, Mysore V. Classifications of Patterned Hair Loss: A Review. J Cutan Aesthet Surg. 2016 Jan-Mar;9(1):3-12. doi: 10.4103/0974-2077.178536. Review.</citation>
    <PMID>27081243</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 4, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

